Treatment of HBeAg-positive patients with nucleos/tide analogues

Liver International

Volumn 29, Issue SUPPL. 1, 2009, Pages 116-124

  Coffin, Carla S ^a   Lee, Samuel S ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Hepatitis B treatment; Hepatitis B virus; Nucleos tide analogues; Pegylated interferon

Indexed keywords

ADEFOVIR DIPIVOXIL; CLEVUDINE; EMTRICITABINE; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PLACEBO; TELBIVUDINE; TENOFOVIR;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; BONE MARROW SUPPRESSION; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERADICATION THERAPY; FLU LIKE SYNDROME; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; KIDNEY DISEASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MENTAL DISEASE; MONOTHERAPY; MYALGIA; NEPHROTOXICITY; ONSET AGE; RECURRENCE RISK; RISK FACTOR; SEROCONVERSION; THYROID DISEASE; VIRAL GENETICS; VIRUS INHIBITION;

ANTIVIRAL AGENTS; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 59149094885     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01935.x     Document Type: Conference Paper

References (58)

1. Feld JJ, Heathcote EJ. Hepatitis B e antigen-positive chronic hepatitis B: Natural history and treatment. Semin Liver Dis 2006; 26: 116-29.
2. Sheldon J, Ramos B, Garcia-Samaniego J, et al. Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/ HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. J Acquir Immune Defic Syndr 2007; 46: 279-82.
3. Thibault V, Aubron-Olivier C, Agut H, et al. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16: 131-3.
4. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33: 751-7.
5. Ganem D, Prince A. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004; 350: 1118-29.
6. McMahon BJ. Selecting appropriate management strategies for chronic hepatitis B: Who to treat. Am J Gastroenterol 2006; 101(Suppl. 1): S7-12.
7. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update. Liver Int 2005; 25: 472-89.
8. Keeffe E, Dieterich D, Han S, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the US: An update. Clin Gastroenterol Hepatol 2006; 4: 936-62.
9. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 23 August 2008 [Epub ahead of print].
10. Lok A, McMahon B. Chronic hepatitis B. AASLD practice guidelines. Hepatology 2001; 34: 1225-41.
11. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008; 359: 1486-500.
12. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
13. Yuen M-F, Yuan H-J, Wong DK-H. Prognostic determinants for chronic hepatitis B in Asians: Therapeutic implications. Gut 2005; 54: 1610-4.
14. Lai M, Hyatt BJ, Nasser I, et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-7.
15. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-31.
16. Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-9.
17. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B, 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39(Suppl. 1): S3-25.
18. Song BC, Suh DJ, Lee HC, et al. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000; 32: 803-6.
19. Alexander G, Baba CS, Chetri K, et al. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: Results of an open labeled trial. BMC Gastroenterol 2005; 5: 29.
20. Dienstag JL, Cianciara J, Karayalcin S, et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 2003; 37: 748-55.
21. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-Hepatitis B Virus International Panel. Aids 2008; 22: 1399-410.
22. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-95.
23. Marcellin P, Lau G, Bonino F, et al. Peginterferon alfa-2a alone, lamuvidine alone and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-17.
24. Cooksley W, Piratvisuth R, Lee S-D, et al. Peginterferon alfa-2a (40kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10: 298-305.
25. Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47: 428-34.
26. Asselah T, Lada O, Boyer N, et al. Treatment of chronic hepatitis B. Gastroenterol Clin Biol 2008; 32: 749-68.
27. Schiff E, Simsek H, Lee WM, et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 21 August 2008 [Epub ahead of print].
28. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004; 40: 1421-5.
29. van Bommel F, Wunsche T, Schurmann D, et al. Tenofovir treatment in patients with lamivudine-resistant hepatitis B mutants strongly affects viral replication. Hepatology 2002; 36: 507-8.
30. van Bommel F, Zollner B, Sarrazin C, et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006; 44: 318-25.
31. Dienstag J, Schiff E, Wright T, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256-63.
32. Lai C, Chien R, Leung N, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61-8.
33. Liaw Y, Leung N, Chang T, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172-80.
34. Allen M, Deslauriers M, Andrews C, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27: 1670-7.
35. Zeng M, Mao Y, Yao G, et al. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B. Hepatology 2006; 44: 108-16.
36. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808-16.
37. Hadziyannis S, Tassopoulos N, Heathcote E, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-7.
38. Hadziyannis S, Tassopoulos N, Heathcote E. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 2673-81.
39. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-51.
40. Izzedine H, Hulot J, Launay-Vacher V, et al. Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney Int 2004; 66: 1153-8.
41. Borroto-Esoda K, Miller M, Arterburn S. Meta-analysis across adefovir clinical trials demonstrates the absence of novel adefovir-associated mutations and confirms the role of the RTA181V and RTN236T mutations in HBV polymerase in association with virologic failure. Hepatology 2006; 44: 552A (abstract #976).
42. Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 1085-9.
43. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-20.
44. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-10.
45. Chang T, Chao T, Kaymakoglu S, et al. Entecavir mainained virologic suppression through 3 years of treatment in antiviral-naive HBeAg positive patients. Hepatology 2006; 44(suppl.1): 229A.
46. Sherman M, Yurdaydin C, Sollano J, et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006; 130: 2039-49.
47. Colonno R, Rose R, Polkornowski K, et al. Assessment at three years shows high barrier to resistance is maintained in entecavir treated nucleoside naive patients while resistance emergence increases over time in lamuvidine refractory patients. Hepatology 2006; 44: 229A (abstract #110).
48. Lai C, Leung N, Teo E. One-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129: 528.
49. Lai C-L, Gane E, Liaw Y-F, et al. Telbivudine vs. lamivudine for chronic hepatitis B: First-year results from the international phase III GLOBE trial. Hepatology 2005; 42: 77A (late breaking abstract #71).
50. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-88.
51. Ristig MB, Crippin J, Aberg JA, et al. Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/ hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed. J Infect Dis 2002; 186: 1844-7.
52. Dore GJ, Cooper DA, Pozniak AL, et al. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy-naive and experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-92.
53. Heathcote E, Gane E, DeMan R, et al. A randomized, double-blind, comparison of tenofovir (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg positive chronic hepatitis B (CHB): Study GS-US-174-010. Hepatology 2007; 46: S1861A.
54. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of tenofovir DF (TDF) versus adefovir dipivoxil (ADV) for the treatment of HBeAg-negative chronic hepatitis B (CHB): Study GS-US-174-010. Hepatology 2007; 46(suppl. 1): 290A.
55. Lim SG, Ng TM, Kung N, et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch Intern Med 2006; 166: 49-56.
56. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172-8.
57. Yoo BC, Kim JH, Kim TH, et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007; 46: 1041-8.
58. Fung SK, Chae HB, Fontana RJ, et al. Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 2006; 44: 283-90.